-
-
Call more information
660-596-2224 -
DG Journal Club AUTHORS: Philip J Peyton, Grace Liskaser, Alexander Ho, Harry Marsh Anesthesiology. 2023 Jan 16 BACKGROUND Nitrous oxide (N2O) promotes absorption atelectasis in poorly ventilated lung segments at high inspired concentrations. The ENIGMA Trial found a higher incidence of postoperative pulmonary complications (PPCs) and wound sepsis with N2O anesthesia in major surgery compared to […]
Read MoreAuthors: Jacquot M et al Pract Pain Manag. 2023 January/February;23(1). In our 2022 drug report, we review emerging pain management agents, including CBD and THC preparations, nearing the market. Plus, a look at updated formulations in development for more targeted pain treatment. With more than 1 in 5 Americans experiencing chronic pain, pain management is […]
Read MorePractical Pain Management Jan 2023 DEA Update on Buprenorphine Prescribing Waivers Clinicians now face one less hurdle in treating patients with opioid use disorder (OUD). As a part of the Consolidation Appropriations Act of 2023, the federal DATA-waiver, or X-waiver, has been removed, making it easier for clinicians to use buprenorphine (marketed under a variety […]
Read MoreAuthor: Michael Walter Cardiovascular Business When treating patients with prior coronary artery bypass grafting (CABG) surgery and recurrent angina, repeat CABG is associated with a better mortality rate than percutaneous coronary intervention (PCI). PCI, however, is associated with better operative outcomes, meaning clinicians will need to weight the risks and benefits of each treatment option […]
Read MoreAuthor: Riz Hatton Becker’s ASC Review Several healthcare leaders see a bright future for ASCs and expect the market to grow in 2023. Three healthcare leaders connected with Becker’s to answer, “What does 2023 have in store for the ASC industry?” Editor’s note: Responses have been lightly edited for length and clarity. Braden Batkoff, MD. Chief Medical […]
Read More